• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors.

作者信息

Blasi F, Vassalli J D, Danø K

出版信息

J Cell Biol. 1987 Apr;104(4):801-4. doi: 10.1083/jcb.104.4.801.

DOI:10.1083/jcb.104.4.801
PMID:3031083
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2114431/
Abstract
摘要

相似文献

1
Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors.尿激酶型纤溶酶原激活剂：酶原、受体及抑制剂
J Cell Biol. 1987 Apr;104(4):801-4. doi: 10.1083/jcb.104.4.801.
2
The growth factor module of urokinase is the binding sequence for its receptor.尿激酶的生长因子模块是其受体的结合序列。
Ann N Y Acad Sci. 1987;511:192-5. doi: 10.1111/j.1749-6632.1987.tb36247.x.
3
Interaction of urokinase A chain with the receptor of human keratinocytes stimulates release of urokinase-like plasminogen activator.
Exp Cell Res. 1990 Mar;187(1):33-8. doi: 10.1016/0014-4827(90)90112-n.
4
Urokinase receptor up-regulation in head and neck squamous cell carcinoma.尿激酶受体在头颈部鳞状细胞癌中的上调
Head Neck. 2000 Aug;22(5):498-504. doi: 10.1002/1097-0347(200008)22:5<498::aid-hed9>3.0.co;2-w.
5
Plasminogen activation by receptor-bound urokinase.受体结合型尿激酶对纤溶酶原的激活作用。
Semin Thromb Hemost. 1991 Jul;17(3):194-200. doi: 10.1055/s-2007-1002609.
6
The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.尿激酶型纤溶酶原激活物受体将蛋白酶的表达极化至迁移单核细胞的前沿，并促进酶抑制剂复合物的降解。
J Cell Biol. 1990 Aug;111(2):783-92. doi: 10.1083/jcb.111.2.783.
7
Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.纤溶酶原激活物抑制剂对受体结合型尿激酶的抑制作用
J Biol Chem. 1990 Jun 15;265(17):9904-8.
8
Autocrine saturation of pro-urokinase receptors on human A431 cells.人A431细胞上尿激酶原受体的自分泌饱和
Cell. 1986 Jun 6;45(5):675-84. doi: 10.1016/0092-8674(86)90782-8.
9
Reply to comment on 'Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system' (A. A-R. Higazi).对“A. A-R. Higazi的《纯化的可溶性尿激酶受体对纤溶酶原-单链尿激酶激活系统的影响》评论的回复”
FEBS Lett. 1997 Feb 3;402(2-3):293-4. doi: 10.1016/s0014-5793(96)01534-7.
10
Re: urokinase and urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.关于：尿激酶与尿激酶受体：与人类膀胱癌细胞系体外侵袭性的关联。
J Natl Cancer Inst. 1997 Nov 5;89(21):1630-1. doi: 10.1093/jnci/89.21.1630.

引用本文的文献

1
Natural serine proteases and their applications in combating amyloid formation.天然丝氨酸蛋白酶及其在对抗淀粉样蛋白形成中的应用。
ADMET DMPK. 2024 Nov 16;12(6):797-820. doi: 10.5599/admet.2551. eCollection 2024.
2
Structure, Properties and Degradation of Self-Assembled Fibrinogen Nanofiber Scaffolds.自组装纤维蛋白原纳米纤维支架的结构、性质与降解
ACS Appl Bio Mater. 2024 Sep 16;7(9):6186-6200. doi: 10.1021/acsabm.4c00761. Epub 2024 Sep 3.
3
Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts.丝氨酸蛋白酶尿激酶抑制剂乌帕司他和鞘氨醇激酶2抑制剂奥帕替尼对胆管癌患者来源异种移植瘤的联合抗肿瘤作用
Cancers (Basel). 2024 Mar 5;16(5):1050. doi: 10.3390/cancers16051050.
4
Urokinase plasminogen activator surface receptor restricts HIV-1 replication by blocking virion release from the cell membrane.尿激酶型纤溶酶原激活物表面受体通过阻止病毒粒子从细胞膜释放来限制 HIV-1 的复制。
Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2212991120. doi: 10.1073/pnas.2212991120. Epub 2023 Jan 13.
5
Events Occurring in the Axotomized Facial Nucleus.轴索切断后面神经核内发生的事件。
Cells. 2022 Jun 29;11(13):2068. doi: 10.3390/cells11132068.
6
Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA.通过抑制尿激酶型纤溶酶原激活剂提高载槲皮素聚合物纳米粒对三阴性乳腺癌的治疗效果。
RSC Adv. 2020 Sep 17;10(57):34517-34526. doi: 10.1039/d0ra04231e. eCollection 2020 Sep 16.
7
Potential clinical applications of phytopharmaceuticals for the in-patient management of coagulopathies in COVID-19.植物药在 COVID-19 住院患者凝血功能障碍管理中的潜在临床应用。
Phytother Res. 2022 May;36(5):1884-1913. doi: 10.1002/ptr.7408. Epub 2022 Feb 11.
8
Suppression of Urokinase-Type Plasminogen Activator Receptor by Docosahexaenoic Acid Mediated by Heme Oxygenase-1 in 12--Tetradecanoylphorbol-13-Acetate-Induced Human Endothelial Cells.在12-十四酰佛波醇-13-乙酸酯诱导的人内皮细胞中，血红素加氧酶-1介导的二十二碳六烯酸对尿激酶型纤溶酶原激活物受体的抑制作用
Front Pharmacol. 2020 Nov 26;11:577302. doi: 10.3389/fphar.2020.577302. eCollection 2020.
9
Identification and evaluation of UL36 protein from Dermacentor silvarum salivary gland and its interaction with Anaplasma ovis VirB10.鉴定和评估硬蜱唾液腺中的 UL36 蛋白及其与绵羊无浆体 VirB10 的相互作用。
Parasit Vectors. 2020 Feb 27;13(1):105. doi: 10.1186/s13071-020-3975-9.
10
Structural Biology and Protein Engineering of Thrombolytics.溶栓剂的结构生物学与蛋白质工程
Comput Struct Biotechnol J. 2019 Jul 2;17:917-938. doi: 10.1016/j.csbj.2019.06.023. eCollection 2019.

本文引用的文献

1
Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.人组织型纤溶酶原激活物激活纤溶酶原的动力学。纤维蛋白的作用。
J Biol Chem. 1982 Mar 25;257(6):2912-9.
2
Released protease-nexin regulates cellular binding, internalization, and degradation of serine proteases.释放的蛋白酶连接素调节丝氨酸蛋白酶的细胞结合、内化和降解。
Proc Natl Acad Sci U S A. 1981 Apr;78(4):2340-4. doi: 10.1073/pnas.78.4.2340.
3
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.通过单克隆抗体亲和层析从人胶质母细胞瘤细胞中纯化酶原至纤溶酶原激活剂。
Biochemistry. 1982 Dec 7;21(25):6410-5. doi: 10.1021/bi00268a014.
4
A proenzyme form of human urokinase.人尿激酶的一种酶原形式。
J Biol Chem. 1982 Jun 25;257(12):7262-8.
5
The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain.人尿中高分子量尿激酶的一级结构。A链的完整氨基酸序列。
Hoppe Seylers Z Physiol Chem. 1982 Oct;363(10):1155-65. doi: 10.1515/bchm2.1982.363.2.1155.
6
Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.尿激酶原（pro-urokinase）的酶原前体形式实现有效且纤维蛋白特异性的血栓溶解。一项体外及在两种动物物种中的研究。
J Clin Invest. 1984 Jun;73(6):1731-9. doi: 10.1172/JCI111381.
7
Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA.未剪接的人尿激酶聚腺苷酸加尾RNA的鉴定及一级序列
Proc Natl Acad Sci U S A. 1984 Aug;81(15):4727-31. doi: 10.1073/pnas.81.15.4727.
8
Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.
Proc Natl Acad Sci U S A. 1983 Nov;80(22):6804-8. doi: 10.1073/pnas.80.22.6804.
9
Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells.牛内皮细胞产生的一种异常稳定的纤溶抑制剂的检测。
Proc Natl Acad Sci U S A. 1983 May;80(10):2956-60. doi: 10.1073/pnas.80.10.2956.
10
Human fibroblasts produce inhibitor directed against plasminogen activator when treated with glucocorticoids.
Ann N Y Acad Sci. 1981;370:609-16. doi: 10.1111/j.1749-6632.1981.tb29767.x.